Prevention of exacerbations: How are we doing and can we do better?

Proceedings of the American Thoracic Society

Volumn 3, Issue 3, 2006, Pages 257-261

  Burge, P Sherwood ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

COPD exacerbation; Prevention; Prophylaxis; Weather

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FLUTICASONE; FORMOTEROL; INFLUENZA VACCINE; LONG ACTING DRUG; MUCOLYTIC AGENT; PLACEBO; PNEUMOCOCCUS VACCINE; SALMETEROL; STEROID; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

AIR POLLUTION; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLD EXPOSURE; CONFERENCE PAPER; CONVALESCENCE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; ENVIRONMENTAL TEMPERATURE; EXERCISE; HEALTH CARE PERSONNEL; HUMAN; INFLUENZA; INFLUENZA VACCINATION; META ANALYSIS; MORTALITY; PROPHYLAXIS; PULMONARY REHABILITATION; RESPIRATORY TRACT DISEASE; SEASONAL VARIATION; STREPTOCOCCUS INFECTION; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; VIRUS INFECTION; VIRUS TRANSMISSION;

BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; INFLUENZA, HUMAN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT DISEASES; RISK FACTORS; SEASONS; SIBERIA; TEMPERATURE; VACCINATION;

EID: 33646373662     PISSN: 15463222     EISSN: 15463222     Source Type: Journal    
DOI: 10.1513/pats.200511-117SF     Document Type: Conference Paper

References (40)

1. Burge PS, Wedzicha JA. COPD exacerbations; definitions and classifications. Eur Respir J 2003;21:46s-53s.
2. Anthonisen NR, Manfreda J, Warren CPW. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
3. Burge PS, Calverley PMA, Jones PW, Spencer SA, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.
4. Pauwels RA, Lofdahl C, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV; European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-1953.
5. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effects of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-1823.
6. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflamatory markers to symptoms and lung function in COPD exacerbations. Thorax 2000;55:114-120.
7. Wilkinson TM, Donaldson GC, Hurst JR, Seemungle TA, Wedzicha JA. Early therapy improves outcome of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:1298-1303.
8. 1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153:1530-1535.
9. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. The Cochrane Library. Chichester, UK: John Wiley and Sons, 2004.
10. Decramer M, Rutten-van-Molken M, Dekhuijzen PN, Troosters T, van Herwaarden CL, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomised on NAV Cost-Utility Study, BRONCUS): a randomised placebo-controlled study. Lancet 2005;365:1552-1560.
11. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarythromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24:639-652.
12. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-784.
13. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effect of a large scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001;357:1008-1011.
14. Salgado CD, Giannetta ET, Hayden FG, Farr BM. Preventing nosocomial influenza by improving the vaccine acceptance rate of clinicians. Infect Control Hosp Epidemiol 2004;25:923-929.
15. Dear KBG, Andrews RR, Holden J, Tatham DP. Vaccines for preventing pneumococcal infections in adults. Cochrane Database Syst Rev 2003;4:CD000422. Review.
16. Bogaert D, van der Valk P, Ramdin R, Sluijter M, Monninkhof E, Hendrix R, de Groot R, Hermans PW. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect Immun 2004;72:818-823.
17. Wilkinson P, Pattenden S, Armstrong B, Fletcher A, Kovata RS, Mangtani P, McMichael AJ. Vulnerability to winter mortality in elderly people in Britain: population based study. BMJ 2004;329:647-653.
18. Donaldson GC, Tchernjavskii VE, Ermakov SP, Bucher K, Keatinge WR. Winter mortality and cold stress in Yekaterinburg, Russia: interview study. BMJ 1998;316:514-518.
19. Donaldson GC, Ermakov SP, Komarov YM, McDonald CP, Keatinge WR. Cold related mortalities and protection against cold in Yakutsk, eastern Siberia: observation and interview study. BMJ 1998;317:978-982.
20. Eurowinter Group. Cold exposure and winter mortality from ischaemic heart disease, respiratory disease, and all causes in warm and cold regions of Europe. Lancet 1997;349:1341-1346.
21. Griffiths TL, Burr ML, Cambell IA, Lewis-Jenkins V, Mullins J, Shiels K, Turner-Lawlor PJ, Payne N, Newcombe RG, Lonescu AA, et al. Results at 1 year of multidiciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000;355:362-368.
22. Puhan MA, Scharplatz M, Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality: a systematic review. Respir Res 2005;6:54.
23. Boxall AM, Barclay L, Sayers A, Caplan GA. Managing chronic obstructive pulmonary disease in the community: a randomised controlled trial of home-based pulmonary rehabilitation for elderly housebound patients. J Cardiopulm Rehabil 2005;25:378-385.
24. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65.
25. Weir DC, Bale GA, Bright P, Burge PS. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clin Exp Allergy 1999;29:125-128.
26. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
27. Calverley PMA, Pauwels R, Vestbo J, Jones P, Pride NB, Gulsvik A, Anderson JA, Maden C; TRISTAN Study Group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456.
28. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, Herwaaden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study. Am J Respir Crit Care Med 2002;166:1358-1363.
29. Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998;53:477-482.
30. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998;351:773-780.
31. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-1909.
32. Calverley PMA, Boonswat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919.
33. Casaburi R, Mahler DA, Jones PW,Wanner A, San Padro G, ZuWallack RL, Menjoge SS, Serby CW, Witek TJ Jr. A long-term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224.
34. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404.
35. Vincken W, van Noord JA, Greefhorst APM, Bantje TA, Kesten S, Korducki L, Cornelissen PJG. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-216.
36. Littlejohns P, Baveystock CM, Parnell H, Jones PW. Randomised controlled trial of the effectiveness of a respiratory health worker in reducing impairment, disability, and handicap due to chronic airflow limitation. Thorax 1991;46:559-564.
37. Gallefoss F, Bakke PS. Impact of patient education and self-management on morbidity in asthmatics and patients with chronic obstructive pulmonary disease. Respir Med 2000;94:279-287.
38. Monninkhof EM, van der Valk PDLMP, van der Palen J, van Herwaarden CLA, Partidge MR, Walters EH, Zielhuis GA. Self-management education for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;4.
39. 1. The Lung Health Study. JAMA 1994;272:1497-1505.
40. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration in health status in COPD. Eur Respir J 2004;23:1-5.